Coagulation Factor IX Human

Generic Name
Coagulation Factor IX Human
Brand Names
Alphanine Sd, Balfaxar, Beriplex, Immunine Vh, Kcentra, Octaplex
Drug Type
Biotech
Chemical Formula
-
CAS Number
181054-95-5
Unique Ingredient Identifier
6U90Y1795T
Background

Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.

Indication

Factor IX is used to treat Christmas disease. Factor IX deficiency is treated by injection factor IX produced from human plasma. Tranexamic acid may be of value in patients undergoing surgery who have inherited factor IX deficiency in order to reduce the perioperative risk of bleeding.

Associated Conditions
Acquired Coagulation Factor Deficiency, Bleeding caused by Hemophilia B, Major Bleeding, Vitamin K antagonist induced major bleeding
Associated Therapies
-
drugs.com
·

Trial Confirms 'Life-Changing' Impact of Gene Therapy for Hemophilia B

Gene therapy Beqvez (fidanacogene elaparvovec) significantly reduces bleeding episodes in hemophilia B patients by 71% after a single infusion, with over half experiencing no bleeds, according to a clinical trial published in the New England Journal of Medicine. The therapy, approved by the FDA in April 2024, uses a virus to deliver a working factor IX gene to the liver, enabling continuous production of the clotting factor. Patients report a 'hemophilia-free state of mind' post-treatment.
drugs.com
·

Trial Confirms 'Life-Changing' Impact of Beqvez Gene Therapy for Hemophilia B

Beqvez gene therapy significantly reduces bleeding episodes in hemophilia B patients, with 71% average drop and 50% bleed-free outcomes post-infusion, per NEJM study. FDA approved in April 2024, offering a single-dose alternative to regular factor IX infusions.
drugs.com
·

Trial Confirms 'Life-Changing' Impact of Gene Therapy, Beqvez, for Hemophilia B

Gene therapy Beqvez significantly reduces bleeding episodes in hemophilia B patients by 71% post-infusion, with over half experiencing no bleeds. The therapy, approved in April 2024, delivers a working factor IX gene to the liver via a virus, potentially offering a single-dose, life-changing treatment.
pink.citeline.com
·

ARMOUR's MONONINE MONOCLONAL FACTOR IX APPROVED BY FDA

ARMOUR's Mononine monoclonal Factor IX approved by FDA on Aug. 20 for Hemophilia B, priced at $1.04/unit. Mononine is the first MAb-purified Hemophilia B therapy, supplied in 250, 500, and 1000 IU vials. AlphaNine SD and Bebulin VH Immuno also recently approved for Factor IX deficiency.
© Copyright 2024. All Rights Reserved by MedPath